Anti-Human CD137 (4-1BB) (Urelumab) (C3240-100mg)

CD137, also known as 4-1BB or TNFRSF9, is a member of the tumor necrosis factor receptor (TNFR) superfamily. It is a type I transmembrane protein expressed on the surface of activated T cells, natural killer (NK) cells, dendritic cells, and other immune cells. CD137 functions as a co-stimulatory molecule, enhancing T cell proliferation, survival, and cytokine production upon binding to its ligand, CD137L. This interaction plays a crucial role in immune responses, making CD137 an attractive target for cancer immunotherapy1-3. BMS-66513, also known as urelumab, is a humanized IgG4 monoclonal antibody that acts as an agonist for CD137. By binding to CD137, urelumab enhances the activation and proliferation of T-cells and NK cells, leading to increased antitumor activity. It has shown potential in potentiating tumor cell killing and enhancing the cytotoxicity of other therapeutic antibodies like rituximab. Urelumab is being investigated for its efficacy in treating various solid tumors and hematological malignancies4-6.